



Company Announcement

Blood Clot Detection Trial on Track

Monday 5 May, 2003

Brisbane-based biotechnology company Agenix Ltd [ASX:AGX] today announced that the Phase 1a trial of its blood clot imaging agent ThromboView® was on track and that preliminary results indicated that the technology was safe.

"The trial, which began in early May, has now successfully tested the safety and tolerability of ThromboView® at two dosage levels. Each dosage test involved eight healthy volunteers," said Dr David Macfarlane, co-investigator of the ThromboView® trial. "We will now move on to tests for the next series of dosage levels."

ThromboView® will help doctors to accurately diagnose and locate blood clots in humans. The technology uses a clot-binding monoclonal antibody attached to a radiolabel. Following injection of a few millilitres of ThromboView® into a patient with a suspected blood clot, the antibody will flow through a person's body and bind to any existing blood clots. The resulting "hotspots", indicating the presence of the blood clot, will be picked up by an imaging camera.

Overall, the Phase 1a trial will include 32 volunteers aged between 18 and 70.

"These first two dose levels have been very promising," said Don Home, Managing Director of Agenix. "The early results – pending final analysis – are meeting our expectations, and indicate that ThromboView® is safe, and that the trial is going as planned."

The trial is being conducted at Q-Pharm Pty Ltd, a dedicated Phase I clinical trial facility, in conjunction with the Department of Nuclear Medicine at the Royal Brisbane Hospital.

For more information contact:

Mr Donald Home
Managing Director
Agenix Limited
Ph: 61 7 3370 6300

Ms Sue Parry-Jones
Vice President – Molecular Diagnostic Imaging
Agenix Limited
Ph: 61 7 3370 6300

Agenix Limited [ASX:AGX, NASDAQ: AGXLY] is a listed company based in Brisbane, Australia. It manufactures, distributes and markets human and veterinary diagnostic test kits, over-the-counter pharmaceuticals and infant care products via its wholly-owned subsidiaries AGEN Biomedical and Milton Pharmaceuticals. Agenix focuses on developing a horizontally-integrated product portfolio to service the needs of the acute phase thrombosis market. Agenix's lead candidate is its high-technology ThromboView® blood clot-imaging project, which is currently undergoing human trials. ThromboView® uses radiolabelled antibodies to locate blood clots in the body. It could revolutionise the US \$3 billion global clot diagnostic imaging market. Agenix employs 190 staff and sells its products to more than 50 countries. ThromboView® is a registered trademark of AGEN Biomedical.

www.agenix.net